Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale.
Identifieur interne : 001136 ( Ncbi/Merge ); précédent : 001135; suivant : 001137Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale.
Auteurs : Jody D. Berry [Canada]Source :
- Veterinary journal (London, England : 1997) [ 1090-0233 ] ; 2005.
Descripteurs français
- KwdFr :
- MESH :
- immunologie : Anticorps monoclonaux, Antigènes.
- usage thérapeutique : Anticorps monoclonaux.
- Animaux, Bioterrorisme, Humains, Maladies de l'animal, Maladies transmissibles émergentes, Protéines recombinantes, Recherche.
English descriptors
- KwdEn :
- MESH :
- chemical , immunology : Antibodies, Monoclonal, Antigens.
- prevention & control : Animal Diseases, Communicable Diseases, Emerging.
- chemical , therapeutic use : Antibodies, Monoclonal.
- Animals, Bioterrorism, Humans, Recombinant Proteins, Research.
Abstract
Many factors influence the choice of methods used to develop antibody to infectious agents. In this paper, we review the current status of the main technologies used to produce monoclonal antibodies (mAbs) from the B cells of antigen-sensitized animals. While companies are adopting advanced high-throughput methods, the major technologies used by veterinary and medical research laboratories are classical hybridoma fusion and recombinant library selection techniques. These methods have inherent advantages and limitations but have many common aspects when using immunized rodents. Laboratories with expertise in both methods of antibody development have a distinct advantage in their ability to advance mAb technology. New and re-emerging infectious threats in today's world emphasize the need for quality immunoreagents and the need to maintain expertise in mAb development. We provide examples of some common applications for mAb reagents used to identify pathogens such as the SARS-coronavirus (SARS-CoV), Bacillus anthracis, and foot-and-mouth disease (FMD) virus. We also outline a framework for investigators to make rational decisions concerning which method to use to develop mAbs based upon characteristics of the pathogen under study and the intended downstream application. Lastly, we provide parameters for the immunisation of mice and a classification system which describes the expected outcome for mAb development strategies when using classes of immunogens to generate mAbs with desired activities.
DOI: 10.1016/j.tvjl.2004.04.021
PubMed: 16129340
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002565
- to stream PubMed, to step Curation: 002565
- to stream PubMed, to step Checkpoint: 002548
Links to Exploration step
pubmed:16129340Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale.</title><author><name sortKey="Berry, Jody D" sort="Berry, Jody D" uniqKey="Berry J" first="Jody D" last="Berry">Jody D. Berry</name><affiliation wicri:level="1"><nlm:affiliation>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, 1015 Arlington Street, Winnipeg, MB, Canada R3E 3M4. berryjd@inspection.gc.ca</nlm:affiliation><country>Canada</country><wicri:regionArea>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, 1015 Arlington Street, Winnipeg, MB</wicri:regionArea><wicri:noRegion>MB</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16129340</idno><idno type="pmid">16129340</idno><idno type="doi">10.1016/j.tvjl.2004.04.021</idno><idno type="wicri:Area/PubMed/Corpus">002565</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002565</idno><idno type="wicri:Area/PubMed/Curation">002565</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002565</idno><idno type="wicri:Area/PubMed/Checkpoint">002548</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002548</idno><idno type="wicri:Area/Ncbi/Merge">001136</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale.</title><author><name sortKey="Berry, Jody D" sort="Berry, Jody D" uniqKey="Berry J" first="Jody D" last="Berry">Jody D. Berry</name><affiliation wicri:level="1"><nlm:affiliation>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, 1015 Arlington Street, Winnipeg, MB, Canada R3E 3M4. berryjd@inspection.gc.ca</nlm:affiliation><country>Canada</country><wicri:regionArea>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, 1015 Arlington Street, Winnipeg, MB</wicri:regionArea><wicri:noRegion>MB</wicri:noRegion></affiliation></author></analytic><series><title level="j">Veterinary journal (London, England : 1997)</title><idno type="ISSN">1090-0233</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal Diseases (prevention & control)</term><term>Animals</term><term>Antibodies, Monoclonal (immunology)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Antigens (immunology)</term><term>Bioterrorism</term><term>Communicable Diseases, Emerging (prevention & control)</term><term>Humans</term><term>Recombinant Proteins</term><term>Research</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps monoclonaux (immunologie)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Antigènes (immunologie)</term><term>Bioterrorisme</term><term>Humains</term><term>Maladies de l'animal ()</term><term>Maladies transmissibles émergentes ()</term><term>Protéines recombinantes</term><term>Recherche</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Antigens</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Antigènes</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Animal Diseases</term><term>Communicable Diseases, Emerging</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Bioterrorism</term><term>Humans</term><term>Recombinant Proteins</term><term>Research</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Bioterrorisme</term><term>Humains</term><term>Maladies de l'animal</term><term>Maladies transmissibles émergentes</term><term>Protéines recombinantes</term><term>Recherche</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Many factors influence the choice of methods used to develop antibody to infectious agents. In this paper, we review the current status of the main technologies used to produce monoclonal antibodies (mAbs) from the B cells of antigen-sensitized animals. While companies are adopting advanced high-throughput methods, the major technologies used by veterinary and medical research laboratories are classical hybridoma fusion and recombinant library selection techniques. These methods have inherent advantages and limitations but have many common aspects when using immunized rodents. Laboratories with expertise in both methods of antibody development have a distinct advantage in their ability to advance mAb technology. New and re-emerging infectious threats in today's world emphasize the need for quality immunoreagents and the need to maintain expertise in mAb development. We provide examples of some common applications for mAb reagents used to identify pathogens such as the SARS-coronavirus (SARS-CoV), Bacillus anthracis, and foot-and-mouth disease (FMD) virus. We also outline a framework for investigators to make rational decisions concerning which method to use to develop mAbs based upon characteristics of the pathogen under study and the intended downstream application. Lastly, we provide parameters for the immunisation of mice and a classification system which describes the expected outcome for mAb development strategies when using classes of immunogens to generate mAbs with desired activities.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16129340</PMID><DateCompleted><Year>2005</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1090-0233</ISSN><JournalIssue CitedMedium="Print"><Volume>170</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Veterinary journal (London, England : 1997)</Title><ISOAbbreviation>Vet. J.</ISOAbbreviation></Journal><ArticleTitle>Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale.</ArticleTitle><Pagination><MedlinePgn>193-211</MedlinePgn></Pagination><Abstract><AbstractText>Many factors influence the choice of methods used to develop antibody to infectious agents. In this paper, we review the current status of the main technologies used to produce monoclonal antibodies (mAbs) from the B cells of antigen-sensitized animals. While companies are adopting advanced high-throughput methods, the major technologies used by veterinary and medical research laboratories are classical hybridoma fusion and recombinant library selection techniques. These methods have inherent advantages and limitations but have many common aspects when using immunized rodents. Laboratories with expertise in both methods of antibody development have a distinct advantage in their ability to advance mAb technology. New and re-emerging infectious threats in today's world emphasize the need for quality immunoreagents and the need to maintain expertise in mAb development. We provide examples of some common applications for mAb reagents used to identify pathogens such as the SARS-coronavirus (SARS-CoV), Bacillus anthracis, and foot-and-mouth disease (FMD) virus. We also outline a framework for investigators to make rational decisions concerning which method to use to develop mAbs based upon characteristics of the pathogen under study and the intended downstream application. Lastly, we provide parameters for the immunisation of mice and a classification system which describes the expected outcome for mAb development strategies when using classes of immunogens to generate mAbs with desired activities.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>Jody D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>National Centre for Foreign Animal Disease, Canadian Food Inspection Agency, 1015 Arlington Street, Winnipeg, MB, Canada R3E 3M4. berryjd@inspection.gc.ca</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vet J</MedlineTA><NlmUniqueID>9706281</NlmUniqueID><ISSNLinking>1090-0233</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000941">Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Vet J. 2005 Sep;170(2):151-2</RefSource><PMID Version="1">16129336</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000820" MajorTopicYN="N">Animal Diseases</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000941" MajorTopicYN="N">Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023482" MajorTopicYN="Y">Bioterrorism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021821" MajorTopicYN="N">Communicable Diseases, Emerging</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012106" MajorTopicYN="N">Research</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>125</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>04</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>11</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16129340</ArticleId><ArticleId IdType="pii">S1090-0233(04)00127-3</ArticleId><ArticleId IdType="doi">10.1016/j.tvjl.2004.04.021</ArticleId><ArticleId IdType="pmc">PMC7110446</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Immunol. 1997 Oct 15;159(8):3883-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9378976</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hybrid Hybridomics. 2003 Feb;22(1):23-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12713687</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Biotechnol. 2000 Nov;18(11):1177-80</Citation><ArticleIdList><ArticleId IdType="pubmed">11062437</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 Aug;74(15):7158-63</Citation><ArticleIdList><ArticleId IdType="pubmed">10888657</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>AIDS Res Hum Retroviruses. 1992 Jun;8(6):1147-51</Citation><ArticleIdList><ArticleId IdType="pubmed">1380261</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biotechnology. 1992;24:527-31</Citation><ArticleIdList><ArticleId IdType="pubmed">1422066</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1990 Aug;87(16):6378-82</Citation><ArticleIdList><ArticleId IdType="pubmed">2201029</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hum Antibodies Hybridomas. 1990;1(1):23-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2129418</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1997 Jul 1;159(1):279-89</Citation><ArticleIdList><ArticleId IdType="pubmed">9200464</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 1982 Mar 12;49(2):R11-23</Citation><ArticleIdList><ArticleId IdType="pubmed">7040548</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 1990 Dec 6;348(6301):552-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2247164</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2003 Apr;77(7):4095-103</Citation><ArticleIdList><ArticleId IdType="pubmed">12634368</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Drug Discov Today. 2001 Jan 1;6(1):36-43</Citation><ArticleIdList><ArticleId IdType="pubmed">11165171</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cloning Stem Cells. 2002;4(1):91-102</Citation><ArticleIdList><ArticleId IdType="pubmed">12006160</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 1975 Aug 7;256(5517):495-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1172191</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Immunol. 1996 May-Jun;33(7-8):583-92</Citation><ArticleIdList><ArticleId IdType="pubmed">8760269</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 1988 Oct;6(5):403-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2848376</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Comb Chem High Throughput Screen. 2001 Aug;4(5):409-16</Citation><ArticleIdList><ArticleId IdType="pubmed">11472229</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Viral Immunol. 2001;14(3):263-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11572636</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1990 Aug;87(16):6450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1696733</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nucleic Acids Res. 1991 Aug 11;19(15):4133-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1908075</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hybridoma. 1995 Jun;14(3):235-42</Citation><ArticleIdList><ArticleId IdType="pubmed">7590785</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Res Immunol. 1995 Jan;146(1):5-10</Citation><ArticleIdList><ArticleId IdType="pubmed">7569313</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hybridoma. 1987 Dec;6(6):637-43</Citation><ArticleIdList><ArticleId IdType="pubmed">2449390</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hybridoma. 1987 Feb;6(1):71-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3679254</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 1988 Aug 9;112(1):53-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3261313</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Microbiol Rev. 1988 Jul;1(3):313-29</Citation><ArticleIdList><ArticleId IdType="pubmed">3058298</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>IUBMB Life. 1999 Nov;48(5):513-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10637767</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Microbiol. 2003 Sep;49(5):1347-59</Citation><ArticleIdList><ArticleId IdType="pubmed">12940992</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Mol Biol. 1993 Apr 5;230(3):812-23</Citation><ArticleIdList><ArticleId IdType="pubmed">8478936</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Sin B. 1986 Feb;29(2):165-72</Citation><ArticleIdList><ArticleId IdType="pubmed">2428110</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nucleic Acids Res. 1997 Dec 15;25(24):5132-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9396828</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biotechniques. 2003 Oct;35(4):850-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14579751</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 2000 May 26;239(1-2):153-66</Citation><ArticleIdList><ArticleId IdType="pubmed">10821956</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 1992 May 21;357(6375):201-2</Citation><ArticleIdList><ArticleId IdType="pubmed">1589019</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 1991 Aug 15;352(6336):624-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1907718</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vet Immunol Immunopathol. 1988 Feb;18(1):95-101</Citation><ArticleIdList><ArticleId IdType="pubmed">3376424</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 1996 May 3;271(18):10967-72</Citation><ArticleIdList><ArticleId IdType="pubmed">8631916</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biotechniques. 1994 Apr;16(4):616-8, 620</Citation><ArticleIdList><ArticleId IdType="pubmed">8024780</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1996 Mar 15;156(6):2163-70</Citation><ArticleIdList><ArticleId IdType="pubmed">8690905</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Res Vet Sci. 1987 Sep;43(2):253-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3685639</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1984 Mar;132(3):1561-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6420468</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Immunol. 1994 Apr;24(4):952-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8149964</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2003 Apr;77(7):3993-4003</Citation><ArticleIdList><ArticleId IdType="pubmed">12634359</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunol Rev. 1988 Oct;105:5-26</Citation><ArticleIdList><ArticleId IdType="pubmed">3058579</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biochem Mol Biol Biophys. 2002 Feb;6(1):45-53</Citation><ArticleIdList><ArticleId IdType="pubmed">12186782</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Gene. 1988 Dec 20;73(2):305-18</Citation><ArticleIdList><ArticleId IdType="pubmed">3149606</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunotechnology. 1997 Oct;3(3):195-203</Citation><ArticleIdList><ArticleId IdType="pubmed">9358272</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Biotechnol. 2000 Sep;18(9):989-94</Citation><ArticleIdList><ArticleId IdType="pubmed">10973222</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biotechniques. 1992 Jun;12(6):842-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1642892</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 1997 Feb 14;201(1):35-55</Citation><ArticleIdList><ArticleId IdType="pubmed">9032408</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 1980;35(1-2):1-21</Citation><ArticleIdList><ArticleId IdType="pubmed">7009747</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7843-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8755564</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Adv Immunol. 1994;57:191-280</Citation><ArticleIdList><ArticleId IdType="pubmed">7872158</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1998 Jan;72(1):585-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9420262</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Chem Biol. 2001 Aug;5(4):368-74</Citation><ArticleIdList><ArticleId IdType="pubmed">11470598</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunotechnology. 1995 May;1(1):21-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9373330</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 1990 Jul 27;249(4967):404-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2143033</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8910-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9671778</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1997 May 13;94(10):4937-42</Citation><ArticleIdList><ArticleId IdType="pubmed">9144168</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Gene. 1995 Dec 29;167(1-2):285-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8566793</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10164-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1279672</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 1985 Jun 14;228(4705):1315-7</Citation><ArticleIdList><ArticleId IdType="pubmed">4001944</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hybrid Hybridomics. 2003 Apr;22(2):97-108</Citation><ArticleIdList><ArticleId IdType="pubmed">12831535</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 2003 May 1;276(1-2):185-96</Citation><ArticleIdList><ArticleId IdType="pubmed">12738372</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Anal Biochem. 1986 May 1;154(2):373-81</Citation><ArticleIdList><ArticleId IdType="pubmed">2425654</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2002 Nov 29;277(48):45811-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12237296</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mol Immunol. 1988 Mar;25(3):313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">3287142</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9339-43</Citation><ArticleIdList><ArticleId IdType="pubmed">1384050</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vet Immunol Immunopathol. 1999 Dec 15;72(1-2):243-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10614515</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2001 Nov 12;20(3-4):498-504</Citation><ArticleIdList><ArticleId IdType="pubmed">11672915</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 1984 Nov 30;74(2):307-15</Citation><ArticleIdList><ArticleId IdType="pubmed">6438240</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunol Rev. 1992 Aug;128:5-21</Citation><ArticleIdList><ArticleId IdType="pubmed">1427923</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Mol Biol. 2003 Jan 10;325(2):325-35</Citation><ArticleIdList><ArticleId IdType="pubmed">12488098</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2003 Mar;9(3):294-303</Citation><ArticleIdList><ArticleId IdType="pubmed">12643823</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunogenetics. 1996;43(3):141-51</Citation><ArticleIdList><ArticleId IdType="pubmed">8550098</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Biotechnol. 1995 Oct;6(5):561-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7579668</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Diagn Lab Immunol. 2003 Jul;10(4):587-95</Citation><ArticleIdList><ArticleId IdType="pubmed">12853390</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biotechniques. 2000 Jul;29(1):128-32, 134-6, 138 passim</Citation><ArticleIdList><ArticleId IdType="pubmed">10907088</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 1999 Jan 1;222(1-2):59-63</Citation><ArticleIdList><ArticleId IdType="pubmed">10022372</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Biotechnol. 2003 Dec;21(12):1509-12</Citation><ArticleIdList><ArticleId IdType="pubmed">14608365</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):640-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9892686</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2002 Jan 5;292(1):127-36</Citation><ArticleIdList><ArticleId IdType="pubmed">11878915</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 1982;50(2):161-71</Citation><ArticleIdList><ArticleId IdType="pubmed">7086152</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 1997 Dec;52(2):183-94</Citation><ArticleIdList><ArticleId IdType="pubmed">9495534</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 1986 Mar 13;87(2):169-77</Citation><ArticleIdList><ArticleId IdType="pubmed">3950427</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 1987 Jul 3;237(4810):67-70</Citation><ArticleIdList><ArticleId IdType="pubmed">3603010</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1995 Jun 15;154(12):6355-64</Citation><ArticleIdList><ArticleId IdType="pubmed">7759873</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunol Cell Biol. 1993 Dec;71 ( Pt 6):517-25</Citation><ArticleIdList><ArticleId IdType="pubmed">8314281</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9348-52</Citation><ArticleIdList><ArticleId IdType="pubmed">7568130</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1995 Jan 15;154(2):893-906</Citation><ArticleIdList><ArticleId IdType="pubmed">7529290</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hybridoma. 1990 Oct;9(5):407-17</Citation><ArticleIdList><ArticleId IdType="pubmed">2258182</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Infect Immun. 1994 May;62(5):1576-83</Citation><ArticleIdList><ArticleId IdType="pubmed">7513303</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Hybridoma. 2000 Jun;19(3):201-14</Citation><ArticleIdList><ArticleId IdType="pubmed">10952409</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1994 May 1;152(9):4235-41</Citation><ArticleIdList><ArticleId IdType="pubmed">7512589</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 1998 Jul;79 ( Pt 7):1687-97</Citation><ArticleIdList><ArticleId IdType="pubmed">9680132</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 Jun;74(12):5548-55</Citation><ArticleIdList><ArticleId IdType="pubmed">10823861</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>AIDS. 1990 Oct;4(10):953-60</Citation><ArticleIdList><ArticleId IdType="pubmed">1702001</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 1989 May 15;160(3):1250-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2499327</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1982 Dec;129(6):2372-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6982918</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1989 Oct;86(20):8010-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2510156</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 1990 Jul 27;249(4967):386-90</Citation><ArticleIdList><ArticleId IdType="pubmed">1696028</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Arch Virol. 1991;117(1-2):59-71</Citation><ArticleIdList><ArticleId IdType="pubmed">1706591</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1989 Jun;86(11):4220-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2726771</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><country name="Canada"><noRegion><name sortKey="Berry, Jody D" sort="Berry, Jody D" uniqKey="Berry J" first="Jody D" last="Berry">Jody D. Berry</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001136 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001136 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:16129340
|texte= Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:16129340" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |